Skip to main content
SpringerLink
Log in

Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia

  • Chapter
Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology

Abstract

Chemotherapy-induced anemia (CIA) is a frequent complication of modern myelosuppressive chemotherapy (Groopman and Itri 1999). Complications of CIA include fatigue and its associated physical, emotional, psychological, and social effects (Curt 2000). The effects of CIA are perhaps most noticeable in the treatment of elderly cancer patients at increased risk of mortality, functional dependence, cognitive disturbances, falls, and cerebrovascular and cardiovascular effects (Balducci et al. 2000). The incidence of severe anemia (hemoglobin <8g/dL) has been reported to range from 50% to 60% in patients with certain malignancies receiving chemotherapy while the total incidence of anemia including grade 1 (hemoglobin = 10g/dL to <12g/dL) and 2 (hemoglobin = 8g/dL to hemoglobin <10g/dL) is high across most major solid tumors (Groopman and Itri 1999; CTEP 1998; FDA 2004).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Balducci L, Hardy CL, Lyman GH (2000) Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control 7(6): 539–547

    CAS  PubMed  Google Scholar 

  2. Bamias A, Aravantinos G, Kalofonos C, et al (2003) Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEPO): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 64(2): 102–110

    Article  CAS  PubMed  Google Scholar 

  3. Berndt E, Crown W, Kallich J, Long S, Song X, Lyman GH (2005) The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics 23(2): 183–192

    Article  PubMed  Google Scholar 

  4. Bohlius J, Wilson J, Seidenfeld J, et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98(10): 708–714

    Article  CAS  PubMed  Google Scholar 

  5. Bokemeyer C, Aapro MS, Courdi A, et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2): 258–270

    Article  CAS  PubMed  Google Scholar 

  6. Cella D, Kallich J, McDermott A, Xu X (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15(6): 979–986

    Article  CAS  PubMed  Google Scholar 

  7. Chang J, Couture F, Young S, McWatters KL, Lau CY (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23(12): 2597–2605

    Article  CAS  PubMed  Google Scholar 

  8. Crawford J, Cella D, Cleeland CS, et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95(4): 888–895

    Article  CAS  PubMed  Google Scholar 

  9. Crawford J, Robert F, Perry MC, Belani C, Williams D (2007) A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive firstline chemotherapy. J Thorac Oncol 2(3): 210–220

    Article  PubMed  Google Scholar 

  10. CTEP. Cancer Therapy Evaluation Program (CTEP) (1998) Common Toxicity Criteria, Version 2.0. DCTD, NCI, HIH, DHHS. March 1998. Available at: http://www.fda.gov/cder/cancer/toxicityframe.htm. Accessed February 2004

    Google Scholar 

  11. Curt GA (2000) Impact of fatigue on quality of life in oncology patients. Semin Hematol 37 [4:Suppl 6]: 14–17

    Article  CAS  PubMed  Google Scholar 

  12. Del Mastro L, Venturini M, Lionetto R, et al (1997) Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15(7): 2715–2721

    PubMed  Google Scholar 

  13. Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 16(10): 3412–3425

    CAS  PubMed  Google Scholar 

  14. Fairclough D, Gagnon D, Zagari M, Marschner N, Dicato M (2003) Evaluation of quality of life in a clinical trial with nonrandom dropout: The effect of epoetin alfa in anemic cancer patients. Quality of Life Research 12: 1013–1027

    Article  CAS  PubMed  Google Scholar 

  15. Fallowfield L, Gagnon D, Zagari M, et al (2002) Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 87(12): 1341–1353

    Article  CAS  PubMed  Google Scholar 

  16. FDA. Food and Drug Administration/Center for Drug Evaluation and Research Oncology Tools page. World Health Organization Toxicity Criteria. Food and Early intervention with erythropoietin 527 Drug Administration Web site. Available at: http://www.fda.gov/cder/cancer/ toxicityframe.htm. Accessed February 2004

    Google Scholar 

  17. Fleiss J (1993) The statistical basis of meta-analysis. Statistical Methods in Medical Research 2: 121–145

    Article  CAS  PubMed  Google Scholar 

  18. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15(3): 1218–1234

    CAS  PubMed  Google Scholar 

  19. Gralow JR HC, Williams D (2003) Incremental improvements in QOL related to changes in hemoglobin in breast cancer (BC) patients (pts) receiving adjuvant chemotherapy (ADJCT) and QW epoetin alfa therapy [abstract]. Blood 102: Abstract 4392

    Google Scholar 

  20. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 10/6/1999 [erratum appears in J Natl Cancer Inst 2000 Mar 15;92(6):497]. 91(19): 1616–1634

    Google Scholar 

  21. Haddad R, MP (2004) Erythropoetin to treat anaemia in patients with head and neck cancer [letter: comment]. Lancet 363: 79

    Article  PubMed  Google Scholar 

  22. Henke M, Laszig R, Rube C, et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, doubleblind, placebo-controlled trial. Lancet 362(9392): 1255–1260

    Article  CAS  PubMed  Google Scholar 

  23. Higgins JT S, Deeks, J, Altman G (2003) Measuring inconsistency in metaanalyses. Br Med J 327

    Google Scholar 

  24. Kaanders JHAM, van der Kogel AJ (2004) Erythropoetin to treat anaemia in patients with head and neck cancer [letter: comment]. Lancet 363: 79–80

    Article  Google Scholar 

  25. Kunikane H, Watanabe K, Fukuoka M, et al (2001) Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 6(6): 296–301

    Article  CAS  PubMed  Google Scholar 

  26. Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4(8): 459–460

    Article  PubMed  Google Scholar 

  27. Leyland-Jones B, Salaheddin M (2004) Erythropoetin to treat anaemia in patients with head and neck cancer [letter: comment]. Lancet 363: 80

    Article  PubMed  Google Scholar 

  28. Littlewood T, Bajetta E (2002) Early administration of epoetin alfa optimizes anemia management with respect to hematologic and quality of life outcomes in anemia cancer patients undergoing chemotherapy [abstract]. Blood 100: 18b. Abstract 3524

    Google Scholar 

  29. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, and the Epoetin Alfa Study Group. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19(11): 2865–2874

    CAS  PubMed  Google Scholar 

  30. Littlewood TJ, Nortier J, Rapoport B, et al (2003) Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematological Oncology 21(4): 169–180

    Article  PubMed  Google Scholar 

  31. Lyman GH (2005) Time is money for both the healthy and the sick. Med Care 43(7): 637–639

    Article  PubMed  Google Scholar 

  32. Lyman GH, Berndt ER, Kallich JD, et al (2005) The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 8(2): 149–156

    Article  PubMed  Google Scholar 

  33. Lyman GH, Dale DC, Kuderer NM, et al (2006) Prospective validation of a predictive model for early anemia in patients receiving cancer chemotherapy. Paper presented at: Blood, 2006; 48th Annual Meeting of the American Society of Hematology

    Google Scholar 

  34. Lyman GH, Glaspy J (2006) Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 106(1): 223–233

    Google Scholar 

  35. Mantel N (1964) Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58: 163–170

    Google Scholar 

  36. Rearden T, Charu V, Saidman B, et al (2004) Results of a randomized study of every-three week dosing (Q3W) of darbepoetin alfa for chemotherapyinduced anemia (CIA) [presentation]. 2004 Annual Meeting. Available at http://www.asco.org/ac/1,1003,_12-002643-00_18-0026-00_19-002479,00.asp. Accessed July 2004

    Google Scholar 

  37. Rizzo JD, Lichtin AE, Woolf SH, et al (2002) Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100(7): 2303–2320

    Article  CAS  PubMed  Google Scholar 

  38. Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT (2006) Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 28(6): 801–831

    Article  CAS  PubMed  Google Scholar 

  39. Sabbatini P (2004) Clinical practice guidelines in oncology: cancer and treatmentrelated anemia. National Comprehensive Cancer Network. 01/14/2004

    Google Scholar 

  40. Savonije JH, van Groeningen CJ, van Bochove A, et al (2005) Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. Eur J Cancer 41(11): 1560–1569

    Article  CAS  PubMed  Google Scholar 

  41. Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G (2006) Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist 11(2): 206–216

    Article  CAS  PubMed  Google Scholar 

  42. Seidenfeld J, Piper M, Flamm C, et al (2000) Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Comparative Effectiveness. Effectiveness Review no. 3. (Prepared by Blue Cross and Blue Shield Association Evaluation Center Evidence-based Practice Center under contract no. 290-02-0026

    Google Scholar 

  43. Seidenfeld J, Piper M, Flamm C, et al (2001) Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93(16): 1204–1214

    Article  CAS  PubMed  Google Scholar 

  44. Straus DJ, Testa MA, Sarokhan BJ, et al (2006) Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer 107(8): 1909–1917

    Article  CAS  PubMed  Google Scholar 

  45. ten Bokkel Huinink WW, de Swart CAM, van Toorn DW, et al (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythro-poietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Medical Oncol 15: 174–182

    Article  Google Scholar 

  46. Thatcher N, De Campos ES, Bell DR, et al (1999) Epoetin a prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinumbased chemotherapy for small cell lung cancer. Br J Cancer 80(3–4): 396–402

    Article  CAS  PubMed  Google Scholar 

  47. Vansteenkiste J, Pirker R, Massuti B, et al (2002) Double-blind, placebocontrolled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94(16): 1211–1220

    CAS  PubMed  Google Scholar 

  48. Vansteenkiste J, Tomita D, Rossi G, Pirker R (2004) Darbepoetin alfa in lung cancer patients on chemotherapy: A retrospective comparison of outcomes in patients with mild verses moderate-to-severe anaemia at baseline. Supportive Care in Cancer 12: 253–262

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Duke University School of Medicine, Duke Center for Clinical Health Policy Research, Box 3645, 27710, Durham, North Carolina, USA

    Gary H. Lyman MD, MPH, FRCP (Edin)

  2. Duke Comprehensive Cancer Center, Duke University School of Medicine, Box 3645, 27710, Durham, North Carolina, USA

    Gary H. Lyman MD, MPH, FRCP (Edin)

  3. Division of Hematology-Oncology, University of California Los Angeles School of Medicine, Los Angeles, California, USA

    Prof. John Glaspy MD (Professor of Medicine)

Authors
  1. Gary H. Lyman MD, MPH, FRCP (Edin)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. John Glaspy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary H. Lyman MD, MPH, FRCP (Edin) .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine (Cancer Research), West German Cancer Center, University Hospital of Essen, Essen, Germany

    Mohammad Resa Nowrousian

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag/Wien

About this chapter

Cite this chapter

Lyman, G.H., Glaspy, J. (2008). Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia. In: Nowrousian, M.R. (eds) Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Springer, Vienna. https://doi.org/10.1007/978-3-211-69459-6_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-69459-6_19

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-25223-9

  • Online ISBN: 978-3-211-69459-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation